Jin Medical International Ltd.
ZJYLHealthcareNASDAQMedical Instruments & Supplies · Last scanned Sep 9, 2026
Scan Results
Daily timeframeJin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury. At a $150.8M market cap, Jin Medical International Ltd. ranks as a micro-cap company within healthcare. The company offers wheelchairs and wheelchair components, such as wheels and brakes; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers.
Market Cap
$150.8M
Beta
7.33
P/E (TTM)
10.10
P/E (Fwd)
—
EPS (TTM)
$0.20
EPS (Fwd)
—
ROE
4.0%
ROA
0.5%
Cash
$30.1M
Total Debt
$20.9M
Free CF
-$7.5M
52W Change
-84.4%
Annual Financials
Cash vs Debt
Where ZJYL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ZJYL finished 12.50% below its 150-day moving average ($2.40) and 27.34% below its 200-day moving average ($2.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ZJYL overbought or oversold?
At the September 3, 2026 close, ZJYL's RSI(14) was 14.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Jin Medical International Ltd. holds $30.1M in cash against $20.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$7.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 4.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 0.5% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $19.2M (2022) to $20.7M (2025).
Jin Medical International Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Jin Medical International Ltd. and its sector.